

PRESS RELEASE

Hansa Biopharma to host conference call to provide interim results for first half 2021 and Business Update

Lund, Sweden July 1, 2021 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-June 2021 at 8:00 CET on July 15, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Webcast," and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 850 558 368

United Kingdom: +44 333 300 92 72

United States: +1 646 722 49 57

The webcast will be available on <https://streams.eventcdn.net/hansa/interim-report-for-january-june-2021/>

Updated Calendar and Events 2021

July 15, 2021	Interim report for Jan-Jun 2021
July 15, 2021	William Blair Biotech Focus Conference, 2021 (virtual)
Aug 25, 2021	Handelsbanken Life Science Innovation Seminar, Stockholm
Aug 31, 2021	Presentation at Penser Access, Skåne
Sep 2, 2021	Pareto Healthcare Conference, Stockholm (virtual)
Sep 13-15, 2021	MorganStanley Global Healthcare Conference (virtual)
Sep 14, 2021	HC Wainwright Annual Global Investment Conference (virtual)
Sep 17, 2021	Danske Bank Life Science event "Platform companies" (virtual)
Oct 21, 2021	Interim report for Jan-Sep 2021
Nov 25, 2021	Erik Penser Banks Bolagsdag, Stockholm or virtual

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

Katja Margell, *Head of Corporate Communications*

M: +46 (0) 768-198 326

E: katja.margell@hansabiopharma.com